IDO1 and neoplasm: Thus, IDO1 is considered a tumor immune checkpoint, and the efficacy of IDO1 inhibitors, alone or in combination with other drugs (e.g., immune checkpoint inhibitors), has been extensively studied in cancer immunotherapy48,49.